Role of TAZ in Lysophosphatidic Acid-Induced Migration and Proliferation of Human Adipose-Derived Mesenchymal Stem Cells

다국어 초록 (Multilingual Abstract)

Transcriptional co-activator with a PDZ-binding motif (TAZ) is an important factor in lysophosphatidic acid (LPA)-induced promotion of migration and proliferation of human mesenchymal stem cells (MSCs). The expression of TAZ significantly increased at 6 h after LPA treatment, and TAZ knockdown inhibited the LPA-induced migration and proliferation of MSCs. In addition, embryonic fibroblasts from TAZ knockout mice exhibited the reduction in LPA-induced migration and proliferation. The LPA1 receptor inhibitor Ki16425 blocked LPA responses in MSCs. Although TAZ knockdown or knockout did not reduce LPA-induced phosphorylation of ERK and AKT, the MEK inhibitor U0126 or the ROCK inhibitor Y27632 blocked LPA-induced TAZ expression along with the reduction in the proliferation and migration of MSCs. Our data suggest that TAZ is an important mediator of LPA signaling in MSCs in the downstream of MEK and ROCK signaling.

참고문헌 (Reference)

1 Hao, Y., "Tumor suppressor LATS1 is a negative regulator of oncogene YAP" 283 : 5496-5509, 2008

2 Overholtzer, M., "Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon" 103 : 12405-12410, 2006

3 Johnson, R., "The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment" 13 : 63-79, 2014

4 Lindroos, B., "The potential of adipose stem cells in regenerative medicine" 7 : 269-291, 2011

5 Liu, C. Y., "The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCF{beta}-TrCP E3 ligase" 285 : 37159-37169, 2010

6 Hong, W., "The YAP and TAZ transcription coactivators:key downstream effectors of the mammalian Hippo pathway" 23 : 785-793, 2012

7 Cordenonsi, M., "The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells" 147 : 759-772, 2011

8 Ramos, A., "The Hippo signaling pathway and stem cell biology" 22 : 339-346, 2012

9 Varelas, X., "The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease" 141 : 1614-1626, 2014

10 Pebay, A., "Stem cell regulation by lysophospholipids" 84 : 83-97, 2007

11 Chen, X., "Serum lysophosphatidic acid concentrations measured by dot immunogold filtration assay in patients with acute myocardial infarction" 63 : 497-503, 2003

12 Yu, F. X., "Regulation of the Hippo-YAP pathway by Gprotein-coupled receptor signaling" 150 : 780-791, 2012

13 van Meeteren, L. A., "Regulation and biological activities of the autotaxin-LPA axis" 46 : 145-160, 2007

14 Li, N., "Prosaposin in the secretome of marrow stroma-derived neural progenitor cells protects neural cells from apoptotic death" 112 : 1527-1538, 2010

15 Frankel, A., "Peptide and lipid growth factors decrease cis-diamminedichloroplatinum-induced cell death in human ovarian cancer cells" 2 : 1307-1313, 1996

16 Geng, Y. J., "Molecular mechanisms for cardiovascular stem cell apoptosis and growth in the hearts with atherosclerotic coronary disease and ischemic heart failure" 1010 : 687-697, 2003

17 Orlic, D., "Mobilized bone marrow cells repair the infarcted heart, improving function and survival" 98 : 10344-10349, 2001

18 Murphy, M. B., "Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine" 45 : e54-, 2013

19 Cselenyak, A., "Mesenchymal stem cells rescue cardiomyoblasts from cell death in an in vitro ischemia model via direct cell-to-cell connections" 11 : 29-, 2010

20 Mangi, A. A., "Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts" 9 : 1195-1201, 2003

21 Liu, X., "Lysophosphatidic acid protects mesenchymal stem cells against ischemia-induced apoptosis in vivo" 18 : 947-954, 2009

22 Chen, J., "Lysophosphatidic acid protects mesenchymal stem cells against hypoxia and serum deprivation-induced apoptosis" 26 : 135-145, 2008

23 Binder, B. Y., "Lysophosphatidic acid protects human mesenchymal stromal cells from differentiation-dependent vulnerability to apoptosis" 20 : 1156-1164, 2014

24 Badri, L., "Lysophosphatidic acid induces migration of human lung-resident mesenchymal stem cells through the β-catenin pathway" 30 : 2010-2019, 2012

25 Tang, N., "Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts" 18 : 156-169, 2014

26 Willier, S., "Lysophosphatidic acid (LPA) signalling in cell migration and cancer invasion: a focussed review and analysis of LPA receptor gene expression on the basis of more than 1700 cancer microarrays" 105 : 317-333, 2013

27 Hu, X., "Lysophosphatidic acid (LPA) protects primary chronic lymphocytic leukemia cells from apoptosis through LPA receptor activation of the anti-apoptotic protein AKT/PKB" 280 : 9498-9508, 2005

28 Li, Z., "LPA rescues ER stress-associated apoptosis in hypoxia and serum deprivation-stimulated mesenchymal stem cells" 111 : 811-820, 2010

29 Ohta, H., "Ki16425, a subtype-selective antagonist for EDG-Family lysophosphatidic acid receptors" 64 : 994-1005, 2003

30 Aggarwal, S., "Human mesenchymal stem cells modulate allogeneic immune cell responses" 105 : 1815-1822, 2005

31 Halder, G., "Hippo signaling: growth control and beyond" 138 : 9-22, 2011

32 Anliker, B., "Cell surface receptors in lysophospholipid signaling" 15 : 457-465, 2004

33 Iyer, S. S., "Anti-inflammatory effects of mesenchymal stem cells: novel concept for future therapies" 8 : 569-581, 2008

34 Chan, S. W., "A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells" 68 : 2592-2598, 2008